News
The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback